openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Sponsored

retatrutide — news, coverage & facts — IJR

|NewsJournalsTopicretatrutide

Topic

retatrutide

0 members

What's driving coverage of retatrutide right now?

5 mentions · 24h

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Momentum
Past window
Prior window
Avg / hr

Facts from Wikidata (CC0).

Overview

Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors. It has been shown to achieve a more than 24% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial. The drug is a peptide with amino acid sequence YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3. References Glucagon-like peptide-1 receptor agonists

From Wikipedia (CC BY-SA 4.0).

Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors. It has been shown to achieve a more than 24% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial. The drug is a peptide with amino acid sequence YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3.

retatrutide across IJR

Ask Genius by OpenServe about retatrutide Create in Studio Build a game Watch videos